Celltrion and Teva Announce FDA Approval of Herzuma a Biosimilar to Herceptin for Treatment of HER2Overexpressing Breast Cancer

Celltrion and Teva Announce FDA Approval of Herzuma, a Biosimilar to Herceptin, for Treatment of HER2-Overexpressing Breast Cancer

10:02 EST 17 Dec 2018 | Speciality Pharma Journal

INCHEON, South Korea & JERUSALEM–(BUSINESS WIRE)–Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA® (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to HERCEPTIN®1 (trastuzumab) for the following indications: Adjuvant Breast Cancer of HER2 overexpressing node positive or node negative (ER/PR negative or with one high …

More From BioPortfolio on "Celltrion and Teva Announce FDA Approval of Herzuma, a Biosimilar to Herceptin, for Treatment of HER2-Overexpressing Breast Cancer"